DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial

TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12